AU2014348369B2 - Methods of treatment of ocular conditions with a sustained drug delivery implant - Google Patents

Methods of treatment of ocular conditions with a sustained drug delivery implant Download PDF

Info

Publication number
AU2014348369B2
AU2014348369B2 AU2014348369A AU2014348369A AU2014348369B2 AU 2014348369 B2 AU2014348369 B2 AU 2014348369B2 AU 2014348369 A AU2014348369 A AU 2014348369A AU 2014348369 A AU2014348369 A AU 2014348369A AU 2014348369 B2 AU2014348369 B2 AU 2014348369B2
Authority
AU
Australia
Prior art keywords
implant
bioerodible implant
plga
years
bioerodible
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2014348369A
Other languages
English (en)
Other versions
AU2014348369A1 (en
Inventor
Rahul Bhagat
Wendy M. Blanda
David Chou
Thierry Nivaggioli
Lin Peng
Jane-Guo Shiah
David A. Weber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52001114&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2014348369(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of AU2014348369A1 publication Critical patent/AU2014348369A1/en
Application granted granted Critical
Publication of AU2014348369B2 publication Critical patent/AU2014348369B2/en
Priority to AU2020204362A priority Critical patent/AU2020204362A1/en
Priority to AU2022204607A priority patent/AU2022204607A1/en
Priority to AU2024205640A priority patent/AU2024205640B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A61K9/204—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
AU2014348369A 2013-11-15 2014-11-14 Methods of treatment of ocular conditions with a sustained drug delivery implant Active AU2014348369B2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2020204362A AU2020204362A1 (en) 2013-11-15 2020-06-30 Methods of treatment of ocular conditions with a sustained drug delivery implant
AU2022204607A AU2022204607A1 (en) 2013-11-15 2022-06-29 Methods of treatment of ocular conditions with a sustained drug delivery implant
AU2024205640A AU2024205640B2 (en) 2013-11-15 2024-08-09 Methods of treatment of ocular conditions with a sustained drug delivery implant

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361904887P 2013-11-15 2013-11-15
US61/904,887 2013-11-15
PCT/US2014/065804 WO2015073895A1 (en) 2013-11-15 2014-11-14 Methods of treatment of ocular conditions with a sustained drug delivery implant

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2020204362A Division AU2020204362A1 (en) 2013-11-15 2020-06-30 Methods of treatment of ocular conditions with a sustained drug delivery implant

Publications (2)

Publication Number Publication Date
AU2014348369A1 AU2014348369A1 (en) 2016-06-09
AU2014348369B2 true AU2014348369B2 (en) 2020-04-02

Family

ID=52001114

Family Applications (4)

Application Number Title Priority Date Filing Date
AU2014348369A Active AU2014348369B2 (en) 2013-11-15 2014-11-14 Methods of treatment of ocular conditions with a sustained drug delivery implant
AU2020204362A Abandoned AU2020204362A1 (en) 2013-11-15 2020-06-30 Methods of treatment of ocular conditions with a sustained drug delivery implant
AU2022204607A Abandoned AU2022204607A1 (en) 2013-11-15 2022-06-29 Methods of treatment of ocular conditions with a sustained drug delivery implant
AU2024205640A Active AU2024205640B2 (en) 2013-11-15 2024-08-09 Methods of treatment of ocular conditions with a sustained drug delivery implant

Family Applications After (3)

Application Number Title Priority Date Filing Date
AU2020204362A Abandoned AU2020204362A1 (en) 2013-11-15 2020-06-30 Methods of treatment of ocular conditions with a sustained drug delivery implant
AU2022204607A Abandoned AU2022204607A1 (en) 2013-11-15 2022-06-29 Methods of treatment of ocular conditions with a sustained drug delivery implant
AU2024205640A Active AU2024205640B2 (en) 2013-11-15 2024-08-09 Methods of treatment of ocular conditions with a sustained drug delivery implant

Country Status (24)

Country Link
US (2) US20150140062A1 (enExample)
EP (2) EP3714875A1 (enExample)
JP (2) JP6675307B2 (enExample)
KR (3) KR20240058976A (enExample)
CN (1) CN105764517A (enExample)
AU (4) AU2014348369B2 (enExample)
CA (1) CA2929689A1 (enExample)
CL (1) CL2016001167A1 (enExample)
CY (1) CY1123344T1 (enExample)
DK (1) DK3068403T3 (enExample)
ES (1) ES2819215T3 (enExample)
HU (1) HUE050913T2 (enExample)
IL (2) IL245548A0 (enExample)
MX (2) MX2016006334A (enExample)
MY (1) MY176039A (enExample)
NZ (1) NZ719953A (enExample)
PH (1) PH12016500869A1 (enExample)
PL (1) PL3068403T3 (enExample)
PT (1) PT3068403T (enExample)
RU (1) RU2690841C1 (enExample)
SG (1) SG10201809363SA (enExample)
SI (1) SI3068403T1 (enExample)
UA (1) UA122117C2 (enExample)
WO (1) WO2015073895A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115337254A (zh) * 2015-07-23 2022-11-15 爱瑞制药公司 用于治疗眼病的玻璃体内药物递送系统
JP2019534063A (ja) 2016-09-02 2019-11-28 エンビシャ セラピューティクス インコーポレイテッド インプラントアプリケータ
MX2020012458A (es) 2018-05-24 2021-04-28 Celanese Eva Performance Polymers Llc Dispositivo implantable para liberacion sostenida de un compuesto de farmaco macromolecular.
US11689849B2 (en) 2018-05-24 2023-06-27 Nureva, Inc. Method, apparatus and computer-readable media to manage semi-constant (persistent) sound sources in microphone pickup/focus zones
US11690806B2 (en) 2018-05-24 2023-07-04 Celanese Eva Performance Polymers Llc Implantable device for sustained release of a macromolecular drug compound
IL299769A (en) * 2020-07-16 2023-03-01 Ocular Therapeutix Inc Ocular insert containing a glucocorticoid
WO2022231930A1 (en) 2021-04-26 2022-11-03 Celanese Eva Performance Polymers Llc Implantable device for sustained release of a macromolecular drug compound

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050244469A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
US8034366B2 (en) * 2003-01-09 2011-10-11 Allergan, Inc. Ocular implant made by a double extrusion process

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6726918B1 (en) 2000-07-05 2004-04-27 Oculex Pharmaceuticals, Inc. Methods for treating inflammation-mediated conditions of the eye
WO2002043785A2 (en) 2000-11-29 2002-06-06 Oculex Pharmaceuticals, Inc. Intraocular implants for preventing transplant rejection in the eye
US8119154B2 (en) 2004-04-30 2012-02-21 Allergan, Inc. Sustained release intraocular implants and related methods
US8685435B2 (en) * 2004-04-30 2014-04-01 Allergan, Inc. Extended release biodegradable ocular implants
US20050244500A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Intravitreal implants in conjuction with photodynamic therapy to improve vision
US20090082321A1 (en) * 2007-09-21 2009-03-26 Allergan, Inc. Steroid containing drug delivery systems
CA2827082A1 (en) * 2011-02-11 2012-08-16 Psivida Us, Inc. Methods of treating macular edema using antiedema therapeutics

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8034366B2 (en) * 2003-01-09 2011-10-11 Allergan, Inc. Ocular implant made by a double extrusion process
US20050244469A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
HALLER J A ET AL, "Randomized Controlled Trial of an Intravitreous Dexamethasone Drug Delivery System in Patients With Diabetic Macular Edema", ARCHIVES OF OPHTHALMOLOGY, AMERICAN MEDICAL ASSOCIATION,2010, vol. 128, no. 3, p 289 - 296 *
HALLER JULIA A ET AL, "Dexamethasone Intravitreal Implant in Patients with Macular Edema Related to Branch or Central Retinal Vein Occlusion", OPHTHALMOLOGY, (2011) vol. 118, no. 12, doi:10.1016/J.OPHTHA.2011.05.014,pages 2453 - 2460 *
KUPPERMANN BARUCH D ET AL, "Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema.", ARCHIVES OF OPHTHALMOLOGY MAR 2007, (2007-03), vol. 125, no. 3, pages 309 - 317 *
PACELLA ELENA ET AL, "Preliminary results of an intravitreal dexamethasone implant (Ozurdex(R)) in patients with persistent diabetic macular edema.", CLINICAL OPHTHALMOLOGY, (2013), vol. 7, doi:10.2147/OPTH.S48364, p 1423 - 1428 *
William M Boyd, M.D., "NDA 22-315; OZURDEX (dexamethasone intravitreal implant)", (2009-06-17), URL: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022315s000_CrossR.pdf, (2015-01-16) *

Also Published As

Publication number Publication date
AU2014348369A1 (en) 2016-06-09
RU2690841C1 (ru) 2019-06-06
CA2929689A1 (en) 2015-05-21
WO2015073895A1 (en) 2015-05-21
US20250319031A1 (en) 2025-10-16
CY1123344T1 (el) 2021-12-31
AU2024205640B2 (en) 2025-10-23
HUE050913T2 (hu) 2021-01-28
EP3714875A1 (en) 2020-09-30
IL245548A0 (en) 2016-06-30
PT3068403T (pt) 2020-09-18
SG10201809363SA (en) 2018-11-29
KR20220082934A (ko) 2022-06-17
MX2016006334A (es) 2016-09-06
EP3068403B2 (en) 2025-12-03
AU2022204607A1 (en) 2022-07-21
MY176039A (en) 2020-07-22
KR20160085847A (ko) 2016-07-18
KR20240058976A (ko) 2024-05-07
CN105764517A (zh) 2016-07-13
PH12016500869B1 (en) 2016-07-04
PH12016500869A1 (en) 2016-07-04
JP2016538292A (ja) 2016-12-08
MX2022002306A (es) 2022-03-25
NZ719953A (en) 2022-01-28
KR102475746B1 (ko) 2022-12-08
SI3068403T1 (sl) 2020-11-30
CL2016001167A1 (es) 2017-01-06
JP2020055862A (ja) 2020-04-09
EP3068403A1 (en) 2016-09-21
US20150140062A1 (en) 2015-05-21
DK3068403T3 (da) 2020-09-07
RU2016119132A (ru) 2017-12-20
UA122117C2 (uk) 2020-09-25
AU2024205640A1 (en) 2024-08-29
JP6675307B2 (ja) 2020-04-01
JP7022735B2 (ja) 2022-02-18
AU2020204362A1 (en) 2020-07-23
IL290837A (en) 2022-04-01
ES2819215T3 (es) 2021-04-15
PL3068403T3 (pl) 2021-01-11
EP3068403B1 (en) 2020-06-17

Similar Documents

Publication Publication Date Title
AU2024205640B2 (en) Methods of treatment of ocular conditions with a sustained drug delivery implant
JP6132964B2 (ja) 萎縮性加齢性黄斑変性の処置方法
de Oliveira Dias et al. New drugs and new posterior delivery methods in CME
Suresh et al. Ocular implants as drug delivery device in opthalmic therapeutics: An overview
HK40038783A (en) Methods of treatment of ocular conditions with a sustained drug delivery implant
HK1228770A1 (en) Methods of treatment of ocular conditions with a sustained drug delivery implant
HK1228770B (en) Methods of treatment of ocular conditions with a sustained drug delivery implant
HK1190092B (en) Bevacizumab for use in a method for treating atrophic age related macular degeneration
HK1190092A (en) Bevacizumab for use in a method for treating atrophic age related macular degeneration

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)